ストックスクリーナーアプリを入手
3.865
5.91%
0.225
前日終値:
$3.64
開ける：
$3.68
24時間の取引高:
1.95M
Relative Volume:
0.60
時価総額：
$421.76M
収益：
-
当期純損益:
$-223.12M
株価収益率:
-1.9234
EPS:
-2.0095
ネットキャッシュフロー:
$-190.49M
1週間 パフォーマンス:
+7.08%
1か月 パフォーマンス:
-18.50%
6か月 パフォーマンス:
-9.08%
1年 パフォーマンス:
-40.96%
1日の値動き範囲:
$3.68
$3.88
1週間の範囲:
$3.46
$3.88
52週間の値動き範囲:
$2.19
$8.26
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
名前
Rocket Pharmaceuticals Inc
セクター
電話
646-440-9100
住所
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.865 | 397.21M | 0 | -223.12M | -190.49M | -2.0095 |
VRTX
Vertex Pharmaceuticals Inc
|
441.80 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.70 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
841.03 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
335.18 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.65 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-18 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-08-20 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-07-25 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-05-30 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-05-28 | ダウングレード | Goldman | Neutral → Sell |
| 2025-05-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-05-28 | ダウングレード | Jefferies | Buy → Hold |
| 2025-05-28 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | ダウングレード | Needham | Buy → Hold |
| 2025-05-27 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2024-12-30 | 開始されました | Wedbush | Outperform |
| 2024-12-18 | 開始されました | Jefferies | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-04-02 | 開始されました | Goldman | Neutral |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-01 | 開始されました | Morgan Stanley | Overweight |
| 2022-11-08 | 開始されました | Canaccord Genuity | Buy |
| 2022-11-01 | 開始されました | BTIG Research | Buy |
| 2022-07-08 | 開始されました | Raymond James | Outperform |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-03-02 | 開始されました | Stifel | Buy |
| 2021-02-18 | 開始されました | Needham | Buy |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-12-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-07-02 | 開始されました | JP Morgan | Overweight |
| 2020-06-25 | 再開されました | BofA/Merrill | Buy |
| 2020-06-01 | 再開されました | Oppenheimer | Outperform |
| 2019-11-06 | 開始されました | Chardan Capital Markets | Buy |
| 2019-09-26 | 開始されました | Piper Jaffray | Overweight |
| 2019-04-23 | 開始されました | Robert W. Baird | Outperform |
| 2019-03-15 | 開始されました | BofA/Merrill | Buy |
| 2019-02-05 | 開始されました | Oppenheimer | Outperform |
| 2018-09-13 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-07-10 | 開始されました | William Blair | Outperform |
すべてを表示
Rocket Pharmaceuticals Inc (RCKT) 最新ニュース
Needham Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating - Moomoo
Activity Recap: Is Rocket Pharmaceuticals Inc Equity Warrant a cyclical or defensive stock2026 News Drivers & Consistent Return Strategy Ideas - baoquankhu1.vn
Meme Stocks: Can Rocket Pharmaceuticals Inc expand into new markets2026 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn
Big Picture: Will Rocket Pharmaceuticals Inc benefit from sector rotationQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
RCKT stock dives despite gene therapy approval — Wall Street dismisses sell-off - MSN
Volume Report: Can Rocket Pharmaceuticals Inc deliver consistent EPS growth2026 Stock Rankings & AI Forecast Swing Trade Picks - baoquankhu1.vn
Aug Ideas: Is Rocket Pharmaceuticals Inc exposed to political risk2026 Winners & Losers & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
RCKT Technical Analysis | Trend, Signals & Chart Patterns | ROCKET PHARMACEUTICALS INC (NASDAQ:RCKT) - ChartMill
[ARS] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Rocket Pharmaceuticals (NASDAQ: RCKT) seeks vote on director slate and option exchange - Stock Titan
Rally Mode: Is Rocket Pharmaceuticals Inc stock a good dividend stockPrice Action & Technical Confirmation Alerts - baoquankhu1.vn
US premarket movers: Argan, Rocket Pharmaceuticals, Unity - MSN
Rocket gene therapy, among FDA’s March approvals, earns PRV - biocentury.com
[SC TO-C] ROCKET PHARMACEUTICALS, INC. Tender Offer Communication | RCKT SEC FilingForm SC TO-C - Stock Titan
FDA Grants Accelerated Approval to Rocket Pharma’s Gene Therapy Kresladi for LAD-I - The Indian Practitioner
RCKTW SEC FilingsROCKET PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Rocket Pharmaceuticals Inc (9IP1.DU) valuation measures and financial statistics - Yahoo Finance UK
First Therapy Funded by California Taxpayer Dollars is Approved to Treat Rare Childhood Disorder - Noticias Newswire
Momentum Shift: What are Rocket Pharmaceuticals Incs growth levers2026 Action & Fast Entry High Yield Tips - baoquankhu1.vn
Rocket Pharmaceuticals, Inc. $RCKT Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Why Rocket Pharmaceuticals (RCKT) got a commercial boost from FDA approval of KRESLADI - MSN
Aug Analyst Calls: Can Rocket Pharmaceuticals Inc expand into new markets2026 Market Overview & Verified Momentum Stock Alerts - baoquankhu1.vn
Rocket Pharmaceuticals Inc (9IP1.DU) Interactive Stock Chart - Yahoo! Finance Canada
RCKT: B of A Securities Raises Price Target on Buy Rating | RCKT Stock News - GuruFocus
Buyback Watch: Is Rocket Pharmaceuticals Inc Equity Warrant forming a breakout pattern2026 Setups & Accurate Technical Buy Alerts - baoquankhu1.vn
Risks Report: Is Rocket Pharmaceuticals Inc forming a bullish divergenceTrade Performance Summary & Growth-Oriented Investment Plans - baoquankhu1.vn
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease - The Globe and Mail
Rocket Pharmaceuticals Files $400M Mixed Shelf Offering, Opens Financing Doors - timothysykes.com
Bank of America Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock - MarketBeat
RCKT Shares Fall Even After FDA Approves Gene Therapy for Uncommon Disease - Bitget
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI - Insider Monkey
FDA Approval Makes Rocket Pharma Gene Therapy the First for Ultra-Rare Immune Disorder - MedCity News
Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene Therapy - Yahoo Finance
Aug Analyst Calls: Whats the beta of Rocket Pharmaceuticals Inc Equity Warrant stock2026 Sector Review & Smart Money Movement Tracker - baoquankhu1.vn
Rocket Pharmaceuticals: Kresladi Approval Validates Platform, But Commercial Upside Remains Limited - Seeking Alpha
Rocket Pharma rises as FDA approves gene therapy - MSN
Assessing Rocket Pharmaceuticals (RCKT) Valuation After Accelerated FDA Approval Of KRESLADI - Sahm
Rocket Pharmaceuticals Delivers Bold Moves Amid Volatile Market - timothysykes.com
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $9 to $16 - Moomoo
FDA approves Rocket Pharma’s Kresladi for severe LAD-I - thepharmaletter.com
Rocket Pharmaceuticals Faces A Make-Or-Break FDA Call On KRESLADI - Finimize
BofA raises Rocket Pharmaceuticals price target on execution view By Investing.com - Investing.com Canada
Rocket Has Liftoff With Kresladi Approval, But Market Remains Small - insights.citeline.com
FDA approves Rocket’s Kresladi as first gene therapy for LAD-I - BioWorld MedTech
Rocket Pharmaceuticals (RCKT) Stock Pops on Historic FDA Gene Therapy Win - MEXC Exchange
Leerink raises Rocket Pharmaceuticals stock price target on FDA approval By Investing.com - Investing.com Canada
Rocket Pharmaceuticals (RCKT) Stock Surges After FDA Approves Groundbreaking Gene Therapy - MEXC
RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off - Stocktwits
Rocket Pharmaceuticals Inc (RCKT) 財務データ
収益
当期純利益
現金流量
EPS
Rocket Pharmaceuticals Inc (RCKT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Shah Gaurav | CEO |
Feb 18 '26 |
Sale |
3.34 |
5,990 |
19,995 |
1,046,055 |
| Wilson Martin | General Counsel |
Feb 18 '26 |
Sale |
3.34 |
1,376 |
4,593 |
682,000 |
| Wilson Martin | General Counsel |
Feb 13 '26 |
Sale |
3.31 |
12,253 |
40,582 |
683,376 |
| Militello John | See Remarks |
Feb 13 '26 |
Sale |
3.31 |
3,726 |
12,341 |
92,176 |
| Shah Gaurav | CEO |
Feb 13 '26 |
Sale |
3.31 |
12,279 |
40,668 |
1,052,045 |
2.43%
0.16%
大文字化:
|
ボリューム (24 時間):